Coeptis Therapeutics (COEP) Short Interest Ratio & Short Volume $11.21 -1.67 (-12.97%) Closing price 04:00 PM EasternExtended Trading$11.50 +0.29 (+2.59%) As of 05:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Coeptis Therapeutics Short Interest DataCoeptis Therapeutics (COEP) has a short interest of 150,700 shares, representing 10.18% of the float (the number of shares available for trading by the public). This marks a -62.81% decrease in short interest from the previous month. The short interest ratio (days to cover) is 0.5, indicating that it would take 0.5 days of the average trading volume of 287,652 shares to cover all short positions.Current Short Interest150,700 sharesPrevious Short Interest405,200 sharesChange Vs. Previous Month-62.81%Dollar Volume Sold Short$1.39 millionShort Interest Ratio0.5 Days to CoverLast Record DateJanuary 15, 2025Outstanding Shares2,400,000 sharesFloat Size1,480,000 sharesShort Percent of Float10.18%Today's Trading Volume128,541 sharesAverage Trading Volume287,652 sharesToday's Volume Vs. Average45% Short Selling Coeptis Therapeutics? Sign up to receive the latest short interest report for Coeptis Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartCOEP Short Interest Over TimeCOEP Days to Cover Over TimeCOEP Percentage of Float Shorted Over Time Coeptis Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 1/15/2025150,700 shares $1.39 million -62.8%10.2%0.5 $9.25 12/31/2024150,700 shares $828,850.00 -62.8%10.2%0.5 $5.50 12/15/2024405,200 shares $72,085.08 +48.9%1.4%0.8 $0.18 11/30/2024272,100 shares $54,420.00 +11.0%0.9%0.8 $0.20 11/15/2024245,200 shares $48,794.80 +60.3%0.8%1 $0.20 10/31/2024153,000 shares $30,600.00 +25.5%0.5%0.6 $0.20 10/15/2024121,900 shares $24,501.90 +12.6%0.4%0.4 $0.20 9/30/2024108,300 shares $19,483.17 +192.7%0.4%0.5 $0.18 9/15/202437,000 shares $6,963.40 -57.0%0.1%0.2 $0.19 8/31/202486,000 shares $17,569.80 -32.6%0.3%0.4 $0.20 Get the Latest News and Ratings for COEP and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Coeptis Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 8/15/2024127,500 shares $26,469.00 -19.5%0.4%0.5 $0.21 7/31/2024158,300 shares $38,197.79 +38.7%0.6%0.3 $0.24 7/15/2024114,100 shares $34,572.30 +14.3%0.4%0.3 $0.30 6/30/202499,800 shares $28,842.20 -68.3%0.4%0.2 $0.29 6/15/2024314,700 shares $103,536.30 -42.5%1.1%0.6 $0.33 5/31/2024546,800 shares $147,854.72 +613.8%2.0%1.1 $0.27 5/15/202476,600 shares $27,193.00 -49.1%0.3%0.1 $0.36 4/30/2024150,500 shares $46,865.70 -13.7%0.6%0.6 $0.31 4/15/2024174,300 shares $64,055.25 +61.8%0.7%0.7 $0.37 3/31/2024107,700 shares $32,029.98 +171.3%0.5%0.4 $0.30 3/15/202439,700 shares $14,264.21 -76.1%0.2%0.2 $0.36 2/29/2024166,100 shares $96,321.39 +153.6%0.8%0.8 $0.58 2/15/202465,500 shares $27,182.50 +0.9%0.3%0.4 $0.42 1/31/202464,900 shares $36,993.00 +172.7%0.3%0.5 $0.57 1/15/202423,800 shares $14,518.00 -32.0%0.1%0.2 $0.61 12/31/202335,000 shares $27,436.50 -22.1%0.2%0.3 $0.78 12/15/202344,900 shares $39,512.00 -32.8%0.2%0.4 $0.88 11/30/202366,800 shares $78,156.00 -16.8%0.4%0.7 $1.17 11/15/202380,300 shares $99,572.00 -1.1%0.5%0.9 $1.24 10/31/202381,200 shares $97,846.00 +40.7%0.6%1.2 $1.21 10/15/202357,700 shares $70,394.00 +77.0%0.4%1 $1.22 9/30/202332,600 shares $37,816.00 -44.6%0.2%0.5 $1.16 9/15/202358,800 shares $62,916.00 +31.5%0.4%1 $1.07 8/31/202344,700 shares $46,935.00 -14.2%0.3%0.4 $1.05 8/15/202352,100 shares $57,831.00 -40.4%0.4%0.3 $1.11 7/31/202387,400 shares $107,502.00 -19.1%0.8%0.5 $1.23 7/15/2023108,000 shares $141,480.00 -42.7%1.0%0.5 $1.31 6/30/2023188,600 shares $292,330.00 -79.2%1.7%0.8 $1.55 6/15/2023905,900 shares $1.62 million +233.1%8.4%2 $1.79 5/31/2023272,000 shares $515,440.00 -26.5%2.7%0.6 $1.90Buy NVDA Now? (Ad) After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chipmaker has struggled this year, facing increased competition and regulatory pressure.For all the details - including the name and ticker of the #1 AI stock to buy instead of NVDA, click 5/15/2023369,800 shares $613,868.00 No Change3.6%1 $1.66 COEP Short Interest - Frequently Asked Questions What is Coeptis Therapeutics' current short interest? Short interest is the volume of Coeptis Therapeutics shares that have been sold short but have not yet been closed out or covered. As of January 15th, traders have sold 150,700 shares of COEP short. 10.18% of Coeptis Therapeutics' shares are currently sold short. Learn More on Coeptis Therapeutics' current short interest. What is a good short interest percentage for Coeptis Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 10.18% of Coeptis Therapeutics' floating shares are currently sold short. Is Coeptis Therapeutics' short interest increasing or decreasing? Coeptis Therapeutics saw a drop in short interest in the month of January. As of January 15th, there was short interest totaling 150,700 shares, a drop of 62.8% from the previous total of 405,200 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Coeptis Therapeutics' float size? Coeptis Therapeutics currently has issued a total of 2,400,000 shares. Some of Coeptis Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Coeptis Therapeutics currently has a public float of 1,480,000 shares. How does Coeptis Therapeutics' short interest compare to its competitors? 10.18% of Coeptis Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Coeptis Therapeutics: Applied Therapeutics, Inc. (16.47%), Context Therapeutics Inc. (2.58%), Rani Therapeutics Holdings, Inc. (6.53%), PepGen Inc. (2.64%), SELLAS Life Sciences Group, Inc. (11.32%), Aerovate Therapeutics, Inc. (12.86%), Aadi Bioscience, Inc. (2.72%), Quince Therapeutics, Inc. (7.31%), Ikena Oncology, Inc. (0.48%), PMV Pharmaceuticals, Inc. (3.06%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: AppLovin Co. ($6.03 billion), Charter Communications, Inc. ($3.83 billion), Reddit, Inc. ($3.11 billion), The Kroger Co. ($2.85 billion), International Paper ($2.73 billion), Rivian Automotive, Inc. ($2.02 billion), SoFi Technologies, Inc. ($2.00 billion), Onsemi ($1.59 billion), Live Nation Entertainment, Inc. ($1.58 billion), and First Solar, Inc. ($1.53 billion). View all of the most shorted stocks. What does it mean to sell short Coeptis Therapeutics stock? Short selling COEP is an investing strategy that aims to generate trading profit from Coeptis Therapeutics as its price is falling. COEP shares are trading down $1.57 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Coeptis Therapeutics? A short squeeze for Coeptis Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of COEP, which in turn drives the price of the stock up even further. How often is Coeptis Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including COEP, twice per month. The most recent reporting period available is January, 15 2025. More Short Interest Resources from MarketBeat Related Companies Applied Therapeutics Short Interest Context Therapeutics Short Interest Rani Therapeutics Short Interest PepGen Short Interest SELLAS Life Sciences Group Short Interest Aerovate Therapeutics Short Interest Aadi Bioscience Short Interest Quince Therapeutics Short Interest Ikena Oncology Short Interest PMV Pharmaceuticals Short Interest Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:COEP) was last updated on 1/28/2025 by MarketBeat.com Staff From Our PartnersBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredTexas approves new currencyRural Texas Town Ramps Up Global Currency War A small town has joined a radical $1.9 trillion attack on the...Stansberry Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredThis Crypto Is Set to Explode in JanuaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMust-See: 5-Second Trump PredictionPresident Trump's prediction is about to become a reality... Opening a rare window of opportunity for you t...InvestorPlace | SponsoredBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredPlease take this warning seriously...I’m here to issue a stark warning to you about an unexpected $2 trillion shock that could impact every trader ...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Coeptis Therapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Coeptis Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.